Grace Therapeutics shares are trading higher after the company announced its Phase 3 STRIVE-ON safety trial of GTx-104 in aSAH met its primary endpoint. Additionally, the company announced a $30 million private placement.
Grace Therapeutics shares are trading higher after the company announced its Phase 3 STRIVE-ON safety trial of GTx-104 in aSAH met its primary endpoint. Additionally, the company announced a $30 million private placement.